(Total Views: 693)
Posted On: 06/09/2020 8:29:20 PM
Post# of 154884
Re: Rubraquercus #37194
mavrilimumab: 40% adverse events???
https://pubmed.ncbi.nlm.nih.gov/28213566/
here is a mavrilimumab phase2B for rheumatoid arthritis with 300 patients.
40-50% of mavrilimumab patients have "adverse events" but I have no clue what that means, nor how to compare it to leronlimab.
https://pubmed.ncbi.nlm.nih.gov/28213566/
here is a mavrilimumab phase2B for rheumatoid arthritis with 300 patients.
40-50% of mavrilimumab patients have "adverse events" but I have no clue what that means, nor how to compare it to leronlimab.
(1)
(0)
